MoonLake Immunotherapeutics to host a Capital Markets Day on Tuesday, April 29
MoonLake Immunotherapeutics to host a Capital Markets Day on Tuesday, April 29 Zug,…
OSE Immunotherapeutics Presents Preclinical Updates in Immuno-Oncology at AACR Annual Meeting 2025
OSE Immunotherapeutics Presents Preclinical Updates in Immuno-Oncology at AACR Annual Meeting 2025…
Seeking Investors: First-in-Class Immunotherapeutics for Cancer
ATLANTA, Jan. 27, 2025 /PRNewswire/ -- Cambium Oncology is pleased to share…
OSE Immunotherapeutics Announces Statistically Significant and Clinically Meaningful Results from the Phase 2 Study of Anti-IL7R mAb Lusvertikimab for the Treatment of Ulcerative Colitis
OSE Immunotherapeutics Announces Statistically Significant and Clinically Meaningful Results from the Phase…